SATIVEX / NABIXIMOLS – a cannabis extract spray

 

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis                                                             (full – 2005)

 http://rheumatology.oxfordjournals.org/cgi/content/full/45/1/50

 

Sativex Drug Momograph                     (monograph – 2005)

http://www.ukcia.org/research/SativexMonograph.pdf

 

Sativex: Fact Sheet                     (full – 2005)       http://www.bayer.ca/files/sativex_fs_fd_091289_e.pdf

 

Sativex: Health Care Professional letter                    (letter – 2005)

http://www.bayer.ca/files/sativex_dhcpl_lapds_091289_e.pdf

 

Sativex produced significant improvements in a subjective measure of spasticity (abst – 2005)      http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=170

 

Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance.      (abst – 2005)

http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=170

 

Conditional okay for cannabis prescription drug                       (news – 2005)

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1150250&tool=pmcentrez

 

Cannabis-Based Drug Relieves Arthritis Pain                 (news – 2005)

http://www.medpagetoday.com/Rheumatology/Arthritis/2097

 

Cannabis-based medicine relieves the pain of rheumatoid arthritis and suppresses the disease       (news – 2005)                          http://www.eurekalert.org/pub_releases/2005-11/oup-cmr110705.php

 

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis                                                       (full – 2006)  http://rheumatology.oxfordjournals.org/cgi/content/full/45/1/50?maxtoshow=&hitqs=80&RESULTFORM  AT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=2240&resourcetype=HWCIT

 

Cannabinoids In Medicine: A Review Of Their Therapeutic Potential                  (full – 2006)

http://www.doctordeluca.com/Library/WOD/WPS3-MedMj/CannabinoidsMedMetaAnalysis06.pdf

 

The use of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis   (letter – 2006)  http://rheumatology.oxfordjournals.org/cgi/content/full/45/6/781

 

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis.                                                                  (abst – 2006)  http://www.ncbi.nlm.nih.gov/pubmed/17086911

 

Randomised controlled study of cannabis-based medicine (Sativex®) in patients suffering from multiple sclerosis associated detrusor overactivity                                                                    (abst – 2006)  http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=168

 

Sativex® in patients with symptoms of spasticity due to multiple sclerosis (abst – 2006)

http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=169

 

Combined cannabinoid therapy via an oromucosal spray              (abst – 2006)

http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=4&p_RefId

=1021517

 

Sativex showed positive effects in 65 per cent of patients with chronic diseases (news – 2006)

http://www.cannabis-med.org/english/bulletin/ww_en_db_cannabis_artikel.php?id=230#4

 

Sativex: Fact Sheet               (full – 2007)

http://www.bayer.ca/files/sativex_fs_fd_109461_e%20_GW_.pdf

 

Sativex: Health Care Professional letter                   (letter – 2007)

http://www.bayer.ca/files/sativex_dhcpl_lapds_109461_e%20_GW_-2.pdf

 

Cannabis; adverse effects from an oromucosal spray.                (abst – 2007)

http://www.nature.com/bdj/journal/v203/n6/abs/bdj.2007.749.html

 

Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis- based medicine. (abst – 2007)                              http://www.ncbi.nlm.nih.gov/pubmed/17712817

 

Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. (abst – 2007)                                     http://www.ncbi.nlm.nih.gov/pubmed/17868014

 

Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial                                                    (abst – 2007)  http://www.ncbi.nlm.nih.gov/pubmed/17997224

 

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.

(abst – 2007)               http://www.ncbi.nlm.nih.gov/pubmed/18035205

 

Cannabinoids Associated With “More Restful Sleep,” Study Says             (news – 2007)

http://www.illinoisnorml.org/content/view/648/27/

 

Cannabinoids in the management of difficult to treat pain              (full – 2008)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/?tool=pmcentrez

 

Emerging strategies for exploiting cannabinoid receptor agonists as medicines. (full – 2009)

http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2008.00048.x/full

 

Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. (full – 2009)                                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755639/

 

Summary of Product Characteristics- Sativex Oralmucosal Spray             (full – 2010)

http://www.medicines.org.uk/EMC/medicine/23262/SPC/Sativex+Oromucosal+Spray/

 

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis                                                      (abst – 2010)  http://msj.sagepub.com/cgi/content/abstract/16/6/707?maxtoshow=&hits=80&RESULTFORM       AT=&fullte  xt=cannabis&searchid=1&FIRSTINDEX=0&sortspec=date&resourcetype=HWCIT

 

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. (abst – 2010)                                   http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=314

 

Emerging treatment options for spasticity in multiple sclerosis; clinical utility of cannabinoids      (link to PDF – 2011)  http://www.doaj.org/doaj?func=abstract&id=842067&q1=cannabinoid&f1=all&b1=or&q2=cannabis&f2=a ll&recNo=30&uiLanguage=en

 

Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.                                                             (abst – 2011)  http://www.ncbi.nlm.nih.gov/pubmed/21542664

 

Subjective and physiological effects after controlled Sativex and oral THC administration.          (abst – 2011)                                       http://www.ncbi.nlm.nih.gov/pubmed/21289620

 

A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.  (abst – 2011)  http://www.ncbi.nlm.nih.gov/pubmed/21671456

 

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.     (abst – 2011)

http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=322

 

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.                                                   (abst – 2011)  http://www.unboundmedicine.com/medline/ebm/record/21456949/abstract/THC_and_CBD_oromucosal_s

 

 

 

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease.                                                 (abst – 2011)           http://www.ncbi.nlm.nih.gov/pubmed/21674569

 

Plasma cannabinoid pharmacokinetics following controlled oral delta9- tetrahydrocannabinol and oromucosal cannabis extract administration                                                                               (abst – 2011)  http://www.unboundmedicine.com/medline/ebm/record/21078841/abstract/Plasma_cannabinoid_pharmaco kinetics_following_controlled_oral_delta9_tetrahydrocannabinol_and_oromucosal_cannabis_extract_admi  nistration_

 

Is Pot Good For You?                 (news – 2011)

http://www.time.com/time/magazine/article/0,9171,1003570,00.html

 

Towards the use of non-psychoactive cannabinoids for prostate cancer.             (full – 2012)

http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02121.x/pdf

 

Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report. (full – 2012)                                    http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2710.2012.01365.x/full

 

Cannabinoids: Novel Medicines for the Treatment of Huntington’s Disease. (abst – 2012)                                     http://www.ncbi.nlm.nih.gov/pubmed/22280340

 

Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial.                                                     (abst – 2012)  http://www.sciencedirect.com/science/article/pii/S1526590012000193

 

A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine.   (abst – 2012)                                        http://www.ncbi.nlm.nih.gov/pubmed/22784399

 

Subjective and Physiological Effects of Oromucosal Sprays Containing Cannabinoids (Nabiximols): Potentials and Limitations for Psychosis Research.                                                                (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22716155

 

Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System. (abst – 2012)                                       http://www.ncbi.nlm.nih.gov/pubmed/22583441

 

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.                                                            (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22509985

 

Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough? (abst – 2012)                                     http://www.ncbi.nlm.nih.gov/pubmed/22509986

 

Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.    (abst – 2012)  http://www.unboundmedicine.com/medline/ebm/record/22928118/abstract/Evaluation_of_the_Effects_of_

 

Sativex


THC_BDS:_CBD_BDS__on_Inhibition_of_Spasticity_in_a_Chronic_Relapsing_Experimental_

 

Allergic_Autoimmune_Encephalomyelitis:_A_Model_of_Multiple_Sclerosis_

 

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.     (abst – 2012)                            http://www.ncbi.nlm.nih.gov/pubmed/22954177

 

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. (abst – 2012)                                    http://www.ncbi.nlm.nih.gov/pubmed/22973422

 

Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids  (abst – 2012)                                       http://www.ncbi.nlm.nih.gov/pubmed/23011861

 

Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis.                                               (abst – 2012)       http://www.ncbi.nlm.nih.gov/pubmed/23072659

 

Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?                                                                (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/23146820

 

Treatment of Tourette syndrome with cannabinoids.               (abst – 2012)

http://www.ncbi.nlm.nih.gov/pubmed/23187140

 

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.                                                                                                (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/23180178

 

Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids  (abst – 2012)                                   http://www.ncbi.nlm.nih.gov/pubmed/23011861?dopt=Abstract

 

What place for cannabis extract in MS?            (abst – 2012)

http://dtb.bmj.com/content/50/12/141.abstract

 

Neuromodulators for pain management in rheumatoid arthritis               (abst – 2012)

http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008921.pub2/abstract

 

Cannabinoid formulation benefits opioid-refractory pain                       (news – 2012)

http://medicalxpress.com/news/2012-06-cannabinoid-benefits-opioid-refractory-pain.html

 

Cannabinoid Shown Effective as Adjuvant Analgesic for Cancer Pain                   (news – 2012)

http://www.sciencedaily.com/releases/2012/06/120604142426.htm

 

Pot-based prescription drug looks for FDA OK                   (news – 2012)

http://medicalxpress.com/news/2012-01-pot-based-prescription-drug-fda.html

 

Cannabinoid therapy helps provide effective analgesia for cancer patients with pain (news – 2012)

http://www.news-medical.net/news/20120605/Cannabinoid-therapy-helps-provide-effective-analgesia-for-  cancer-patients-with-pain.aspx

 

Towards the use of non-psychoactive cannabinoids for prostate cancer                     (full – 2013)

http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02121.x/abstract

 

Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.          (abst – 2013)                                http://www.ncbi.nlm.nih.gov/pubmed/23369054

 

The pharmacologic and clinical effects of medical cannabis.                       (abst – 2013)

http://www.ncbi.nlm.nih.gov/pubmed/23386598

 

A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.                                                                (abst – 2013)  http://www.ncbi.nlm.nih.gov/pubmed/23369055

 

Multiple sclerosis and the blood-central nervous system barrier.                      (abst – 2013)

http://www.ncbi.nlm.nih.gov/pubmed/23401746

Share a link for